Skip to main content



Overcoming EGFR G724S-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors

*NATURE COMMUNICATIONS | (2018) 9:4655 | DOI: 10.1038/s41467-018-07078-0 | * The emergence of acquired resistance against targeted drugs remains a major clinical challenge in lung adenocarcinoma patients. In a subgroup of these patients we identified an association between selection of EGFR T790M-negative but EGFR G724S-positive subclones and osimertinib resistance.…
November 22, 2018

Bring Hope Home June 19th Living Room "Resistance to Targeted Therapy" Dr. Colin Blakely will be discussing all the questions about progression in your lung cancer and where to go and what to do. Dr. Blakely will be talking about what is happening in the research field from next generation therapies after progression from your…
June 18, 2018

A Mix-and-Match Approach to Treating Non-Small-Cell Lung Cancer *** This article was first posted on*** During summer 2015, Teri Kennedy was at a yoga festival in Squaw Valley, California, when she started to wheeze and had trouble breathing. The inhaler her doctor gave her didn’t help. When the then 51-year-old from Sacramento returned home, she went…
May 1, 2018
Ivy_Ilkins - EGFR resisters group founder

How Can Patients Drive Research

If someone had told me when I was first diagnosed back in 2013 that I would be helping to drive lung cancer research, I would not have believed them. But, in my 4+ years of living with lung cancer, I have found myself getting increasingly involved in research advocacy work.…
March 6, 2018